LAMA+LABA complex, ‘Vahelva Respimat’ launches with insurance benefit on April
A new LAMA+LABA complex drug, Vahelva Respimat(generic name: tiotropium+olodaterol) is expected to be launched on April 1.
On the 8th, Boehringer Ingelheim(CEO Gi-hwan Park) introduced Vahelva Respimat and Spiriva Respimat(generic name: tiotropium) and announced plans to share the two treatment...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
